Has your management of post-transplant FSGS changed with the advent of new FSGS directed therapies?

The pathogenesis of FSGS and specifically recurrent FSGS post-transplant has remained an unmet need in nephrology. Multiple purported " circulating permeability factors " have been identified over the years, each of them providing a piece of the picture, but none that comprehensively and definitivel...

Our protocol for recurrent FSGS is constantly evolving. We are still doing 9 runs of plasmapheresis for early recurrence (within 6 months), sometimes. using Daratumab. Later recurrence is typically treated with ACEi/ARB, with consideration for daratumamab. We have not yet routinely used the newer ag...